PSMA ligands in prostate cancer - Probe optimization and theranostic applications

Susanne Lütje; Roger Slavik; Wolfgang Fendler; Ken Herrmann; Matthias Eiber

doi:10.1016/j.ymeth.2017.06.026

PSMA ligands in prostate cancer - Probe optimization and theranostic applications

Methods. 2017 Nov 1:130:42-50. doi: 10.1016/j.ymeth.2017.06.026. Epub 2017 Jun 28.

Authors

Susanne Lütje¹, Roger Slavik², Wolfgang Fendler³, Ken Herrmann⁴, Matthias Eiber⁵

Affiliations

¹ Clinic for Nuclear Medicine, University Hospital Essen, Hufelandstrasse 55, 45122 Essen, Germany. Electronic address: [email protected].
² Ahmanson Translational Imaging Division, David Geffen School of Medicine, University of California, 10833 Le Conte Ave, 200 Medical Plaza, Los Angeles, CA, USA. Electronic address: [email protected].
³ Ahmanson Translational Imaging Division, David Geffen School of Medicine, University of California, 10833 Le Conte Ave, 200 Medical Plaza, Los Angeles, CA, USA. Electronic address: [email protected].
⁴ Clinic for Nuclear Medicine, University Hospital Essen, Hufelandstrasse 55, 45122 Essen, Germany. Electronic address: [email protected].
⁵ Ahmanson Translational Imaging Division, David Geffen School of Medicine, University of California, 10833 Le Conte Ave, 200 Medical Plaza, Los Angeles, CA, USA. Electronic address: [email protected].

PMID: 28666778
DOI: 10.1016/j.ymeth.2017.06.026

Abstract

Due to its selective overexpression in prostate cancer (PCa), the prostate-specific membrane antigen (PSMA) has been recognized as a highly promising target for diagnostic and therapeutic applications. So far, various PSMA ligands have been developed for radiolabeling with radioisotopes such as ⁶⁸Ga or ¹⁸F which can be used for specific visualization and diagnosis of PSMA-expressing PCa. In addition, PSMA ligands suitable for radiolabeling with ¹³¹I or ¹⁷⁷Lu have become available to the clinics, allowing PSMA-based radioligand therapies. Here, we provide a comprehensive review of the most frequently used PSMA ligands, their structural modifications, and the impact of those on clinical applications.

Keywords: Imaging; PSMA; Prostate cancer; Theranostics.

Publication types

Review

MeSH terms

Animals
Antigens, Surface
Binding Sites / physiology
Fluorodeoxyglucose F18 / administration & dosage
Fluorodeoxyglucose F18 / metabolism
Gallium Radioisotopes / administration & dosage
Gallium Radioisotopes / metabolism
Glutamate Carboxypeptidase II
Humans
Ligands
Male
Prostatic Neoplasms / diagnostic imaging*
Prostatic Neoplasms / metabolism*
Radioisotopes / administration & dosage
Radioisotopes / metabolism*
Theranostic Nanomedicine / methods*
Theranostic Nanomedicine / standards

Substances

Antigens, Surface
Gallium Radioisotopes
Ligands
Radioisotopes
Fluorodeoxyglucose F18
Gallium-68
FOLH1 protein, human
Glutamate Carboxypeptidase II